SA
Go ProLog In
PLRX
OverviewIntelligenceChart
Q3 2026 EPS Estimate
$-0.33

Analyst Sentiment

Wall St. Consensus
Hold
15 analysts·Moderate coverage
62
Score
8 Buy (53%)6 Hold (40%)1 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
853%
Hold
640%
Sell
17%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.00
+147.9%
Consensus
$3.00
+147.9%
Bull
$3.00
+147.9%
12-Month Target Range15 analysts
$3.00$3.00$3.00
Current $1.21Consensus
Current Price
$1.21
Upside to Consensus
$1.79

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

No analyst estimates available

Earnings Surprises

Earnings surprise history unavailable.

Recent Analyst Actions

Mar 12, 2026Piper Sandler
Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler
Target:$3.00
+119.8%from $1.36
Mar 3, 2025Stifel Nicolaus
Pliant Therapeutics downgraded to Hold from Buy at Stifel
Target:$3.00
+117.4%from $1.38
Mar 3, 2025Leerink Partners
Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink
Target:$2.00
+44.9%from $1.38
Sep 13, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)
Target:$38.00
+220.9%from $11.84
Sep 9, 2024Leerink Partners
Pliant Therapeutics assumed with an Outperform at Leerink
Target:$33.00
+156.4%from $12.87
May 23, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX)
Target:$40.00
+188.8%from $13.85
May 7, 2024Stifel Nicolaus
Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel
Target:$32.00
+130.1%from $13.91
May 7, 2024Oppenheimer
Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer
Target:$48.00
+248.1%from $13.79
May 7, 2024H.C. Wainwright
Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright
Target:$36.00
+161.1%from $13.79
May 7, 2024RBC Capital
Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital
Target:$45.00
+226.3%from $13.79
Dec 7, 2022J.P. Morgan
JP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42
Target:$42.00
+144.5%from $17.18

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance